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It is often difficult to discern true mycobacterial infection from colonization due to Myco-
bacterium gordonae (M. gordonae) since this organism is ubiquitous and is commonly an
innocuous saprophyte. This study reports a rare case of caseating hilar adenopathy and
pulmonary disease caused by M. gordonae in a patient with chronic obstructive pulmonary
disease (COPD) and rheumatoid arthritis (RA) on maintenance steroids and methotrexate.
Pathologic exam and cultures of lymph node excision biopsy and bronchoalveolar lavage
(BAL) confirmed the diagnosis.
Triple antimycobacterial therapy with azithromycin, ethambutol and rifabutin was
administered. The patient had significant clinical and radiologic improvement and
follow-up cultures confirmed microbiologic cure.
Mycobacterium gordonae can be a rare cause of significant pulmonary infection, and
positive sputum or BAL cultures for M. gordonae should not be automatically discarded
and considered as nonpathogenic contaminants or colonizing organisms, especially in
immunocompromised hosts with comorbidities. A detailed review of the case and relevant
literature is provided.
 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Case report
A 54-year-old white male former plumber was referred for
infectious diseases and pulmonary evaluation because of
weight loss, worsening productive cough of grayish whitesputum, night sweats for several months, and newly noted
mediastinal adenopathy. He had a history of oxygen-
dependent COPD and disabling rheumatoid arthritis for
which he continues on maintenance prednisone 20 mg PO
daily and methotrexate 15 mg PO weekly. He smoked oneUniversity,
Fig. 2 – Sections of lymph nodes show multiple well-
defined, discrete granulomas of variable sizes and different
stages. (Hematoxylin-Eosin, original magnification ·100).
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month prior to his presentation. On examination, he
appeared to be frail and weighed 53 kg. He was tachypneic
with a respiratory rate of 23 per minute, pulse of 88 per min-
ute, and a blood pressure of 115/70. His lung exam revealed
diminished breath sounds with scattered bilateral rhonchi
and basilar crackles. The remainder of his exam was unre-
markable except for warm wrist and ankle joints with typical
rheumatoid arthritis deformities of his hand joints.
Laboratory work-up revealed a white blood cell count of
11,700/mm3, with 78.6% neutrophils, 18.4% lymphocytes,
and 3% monocytes; hemoglobin of 13.3 g/dl; and a platelet
count of 380,000/mm3. A comprehensive metabolic panel
was within normal limits and his HIV antibody was negative.
Computed tomography (CT) scan of the chest showed medi-
astinal adenopathy in the pretracheal and subcarinal regions,
measuring 2.1 · 1.5 and 1.4 · 3.5 cm, respectively, with con-
comitant interstitial infiltration and honey-combing of both
lungs (Fig. 1). CT scanning also showed evidence of changes
compatible with the diagnosis of COPD and interstitial lung
disease based on the presence of emphysematous bullae
and evidence of interstitial lung fibrosis.
He underwent bronchoscopy that showed no evidence of
endobronchial lesions. Bronchoalveolar lavage, brushings
and transbronchial biopsies were obtained from the right
lower lobe anterior segment. He also underwent mediastinal
lymph node biopsy by video assisted thoracoscopic surgery.
Pathologic exam of the resected lymph node showed caseat-
ing granulomatous inflammation (Fig. 2) with well-defined,
suppurative, necrotic centers surrounded by palisading epi-
thelioid macrophages (Fig. 3). Mycobacterial cultures of the
resected caseating granulomatous lymph node tissue and
bronchoalveolar lavage both grew a mycobacterium that
formed pigmentation both in the presence and absence of
light. This was identified as Mycobacterium gordonae, and the
identification was confirmed by the Tennessee State Labora-
tory. Neither the local nor State laboratory was able to per-
form genotyping or antimicrobial susceptibility of the
isolated organism. The patient was treated with triple anti-
mycobacterial therapy including azithromycin, ethambutol
and rifabutin for 18 months with microbiologic cure. Predni-
sone at 20 mg PO daily that he had received for 2 years beforeFig. 1 – Mediastinal adenopathy in the pretracheal and
subcarinal regions, measuring 2.1 · 1.5 and 1.4 · 3.5 cm,
respectively, with interstitial infiltration and honey-
combing of both lungs.the first positive culture was tapered down to 5 mg after
improvement of his infection.
Follow-up sputum cultures collected on multiple subse-
quent visits revealed no further growth of M. gordonae. Spu-
tum conversion time was approximately 2 months after the
start of triple antimycobacterial therapy. His pulmonary
symptoms improved, and his CT scan of the chest showed
radiological improvement nine months after initiation of
therapy. He regained 30 lb during the first year of therapy.
Discussion
Mycobacteria are facultative intracellular pathogens that are
capable of residing in mononuclear phagocytes [1]. Recent
advances in techniques such as DNA probes and theFig. 3 – Higher magnification shows well-defined
necrotizing granuloma of Mycobacteria gordonae. Palisading
epithelioid macrophages are seen surrounding suppurative
necrotic center. (Hematoxylin-Eosin, original magnification
·200).
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sequence with hypervariable regions in non-tuberculous
Mycobacteria have led to a dramatic increase in the identifica-
tion of Mycobacteria species [2]. M. gordonae, named after the
American bacteriologist Ruth Gordon [3], also formerly called
Mycobacterium aquae, or the tap water bacillus, is a common
contaminant of water and raw milk, and it may be present
in the soil. It is generally considered saprophytic and rarely
causes significant lung disease. Isolation of this organism in
sputum cultures is not generally considered clinically signifi-
cant [3–5].
M. gordonae belongs to the Runyon group II, which includes
the scotochromogen mycobacteria that produce pigments in
the dark. Mycobacterium scrophulaceum is a member of the
same group. There are two subgroups among scotochromo-
gens [6], – a Tween hydrolyzing and a non-hydrolyzing
group – that can be differentiated by immunodiffusion [7].
M. gordonae is nitrate reductase negative [7] and has a positive
Tween hydrolysis test [8].
The American Thoracic Society (ATS) and Infectious Dis-
ease Society of America (IDSA) have issued an official state-
ment on the diagnosis, treatment, and prevention of non-
tuberculous mycobacterial diseases in 2007 [9]. Diagnosis
should be based on the presence of pulmonary symptoms
with appropriate exclusion of other etiologies in addition to
radiologic and microbiologic evidence of disease caused by
non-tuberculous mycobacteria. Radiologic evidence of dis-
ease includes nodular or cavitary opacities on chest radio-
graph or a high resolution CT scan (HRCT) that shows
multifocal bronchiectasis with multiple small nodules. Micro-
biologic confirmation involves positive culture results from at
least two separate expectorated sputum samples, positive
culture results from at least one bronchial wash or lavage,
or transbronchial or other lung biopsy with mycobacterial
histopathologic features (granulomatous inflammation or
acid fast bacilli) and a positive culture for non-tuberculous
mycobacteria or biopsy showing mycobacterial histopatho-
logic features (granulomatous inflammation or acid fast
bacilli) and one or more sputum or bronchial washings that
are culture positive for non-tuberculous mycobacteria [9].
The ATS/IDSA statement further stresses that these criteria
fit best with Mycobacterium avium complex (MAC), Mycobacte-
rium kansasii, and Mycobacterium abscessus, while there is not
enough known about most other non-tuberculous Mycobacte-
ria to be certain that these diagnostic criteria are universally
applicable for all other non-tuberculous species [9].
Although rare, invasive lung disease caused byM. gordonae
has been documented in medical literature [5,10,11]. Pneumo-
nitis, interstitial fibrosis, interstitial nodular infiltrates and,
rarely, cavitation have all been caused by this organism
[4,10,12]. Aguado and colleagues [5] reported a patient with
Hodgkin’s disease whose lung biopsy revealed multiple
caseating granulomas with a large number of acid fast bacilli
on stain, and an abundant tissue culture of growth of M.
gordonae. Marchevsky et al. [10] reported growth ofM. gordonae
with evidence of tissue invasion in lung biopsies of 3 patients
with interstitial fibrosis and organizing pneumonia among 40
case series with non-tuberculous mycobacterial lung disease.
Similarly, a 26-year-old female patient had left-sided hilar
adenopathy and nodules in the left lower lobe. Transbronchialbiopsy revealed acid fast bacilli and necrotizing granuloma-
tous inflammation. Two months after starting tuberculosis
therapy, the cultures from the tissue biopsy grew M. gordonae.
Follow-up CT chest revealed significant improvement with
complete resolution of her lung disease [11].
M. gordonae was also reported as an opportunistic patho-
gen in patients with AIDS with an unexplained pulmonary
infection [13]. Besides AIDS, underlying immune suppression,
advanced structural lung disease, such as emphysema and
pneumoconiosis, alcoholism, chronic lung disease, diabetes
mellitus, and malignancy have all been reported as risk fac-
tors for invasive infections with M. gordonae [13,14].
Extrapulmonary infections withM. gordonae including skin
infection, septic arthritis, osteomyelitis, olecranon bursitis,
tenosynovitis, peritonitis, and prosthetic valve infection have
also been reported [15–18]. Pseudoinfection due toM. gordonae
can occur with contaminated ice, aerosol therapy and dye
used during bronchoscopy [19]. In some institutions, contam-
ination of clinical specimens by M. gordonae is a significant
ongoing problem. However, this institution’s microbiology
laboratory has not encountered problems with this organism
contaminating clinical specimen cultures.
Infections caused by M. gordonae have responded well to
multiple antimycobacterial agents including rifabutin, eth-
ambutol, clarithromycin, azithromycin, linezolid and fluoro-
quinolones such as levofloxacin [20–22]. In vitro resistance to
isoniazid and pyrazinamide is likely [23]. Several documented
cases of M. gordonae-associated pulmonary disease cleared
with appropriate therapy [24–26].
It is known that rheumatoid arthritis may have extra-artic-
ular manifestations, and rheumatoid lung nodules are the
most common pulmonary manifestations of RA. RA by itself
may cause granulomas in the mediastinal lymph nodes.
Rheumatoid nodules in mediastinal lymph nodes are extre-
mely uncommon [27]. This specific patient had pathology
revealing granulomas with caseating necrosis, a finding not
typical in the setting of RA.
It is believed that tuberculous infection is extremely unli-
kely in this patient. While the PPD testing was negative,
clearly this has poor sensitivity in the setting of an immuno-
compromised individual. Interferon gamma release assays
could have been employed, but similarly lose sensitivity with
an immunocompromised individual. In addition, this patient
had multiple cultures and biopsies performed that did not
yield M. tuberculosis.
Caseating mediastinal lymphadenitis with concomitant
lung disease caused by M. gordonae infection has not been
reported before. This reported case and reviewed literature
illustrates the role of M. gordonae as an emerging pathogen,
especially in immunocompromised hosts. Positive clinical
cultures for this organism should be carefully reviewed and
acted upon according to the clinical context.
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